‘A Game Changer:’ Cures 2.0 Would Provide $11bn In ‘Subscription’ Contracts For New Antibiotics
Executive Summary
The PASTEUR Act would delink some of an antibiotic’s revenue from prescription sales, with the goal of revitalizing the antibiotic pipeline with additional private investment while encouraging good public health stewardship of critically needed medicines.
You may also be interested in...
Industry Refuses To Let Congress Forget PASTEUR Act
Melinta CEO and a representative of the Infectious Diseases Society of America call on a Senate HELP subcommittee to push for passage of PASTEUR Act. Introduced in the Senate and House for the third time this year, the measure would establish a subscription model to pay drug developers upfront for certain antimicrobials.
Requiem For Cures 2.0: An Idea Whose Time Has Come, But Will Still Have To Wait
The Upton-DeGette legislation wasn’t going to be part of the omnibus bill moving through Congress this week, but its original concepts – creating more clarity on CMS reimbursement – seem as critical as ever.
ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment
Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.